Company Overview
INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; GOSH; and University of Pittsburg. The company was incorporated in 2015 and is headquartered in Boca Raton, Florida.
Why Investors Should Care
Revenue has grown at a 35.4% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.08.
Recent Developments
- Dec 2025 Revenue of $50.00K (+257.1% YoY); net profit $-45.93M.
- Trailing 12 Months Year-on-year growth — revenue +257.1%.
- 5-Year Trend Long-term compounding — revenue CAGR 35.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 35.37% |
| 1 Year: | 257.14% |
Stock Price Performance
| 1 Year: | -4.69% |
| 6 Months: | +83.46% |
| 3 Months: | +93.65% |
| 1 Month: | +27.75% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)63.82 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 35.4% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | INMB INmune Bio Inc. R2KPHARMA | 2.44 | -1.50 | $64.87M | 0.00% | - | - | 35.37% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | - | 0 | 0 | - | - | - | - | 4.00K | - | 14.00K | 163.00K | 16.00K | 98.00K | 38.00K | 46.00K | 43.00K | 14.00K | - | - | 50.00K | - | - | - | - |
| Operating Income | -2.85M | -6.17M | -1.54M | -1.91M | -428.42K | -3.08M | -2.09M | -2.11M | -4.82M | -4.55M | -6.55M | -9.02M | -6.48M | -6.39M | -7.44M | -6.42M | -6.41M | -8.53M | -11.02M | -9.87M | -12.29M | -9.90M | -24.57M | -7.43M | -5.81M | -1.48M |
| Net Income | -2.85M | -6.17M | -1.54M | -1.90M | -392.08K | -3.07M | -2.07M | -2.11M | -4.72M | -4.56M | -6.66M | -9.46M | -6.90M | -6.84M | -7.72M | -6.54M | -6.50M | -8.56M | -11.03M | -9.75M | -12.09M | -9.74M | -24.46M | -6.47M | -5.41M | -1.27M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | -0.55 | -0.39 | -0.38 | -0.43 | -0.36 | -0.36 | -0.48 | -0.61 | -0.50 | -0.60 | -0.43 | -1.05 | -0.24 | -0.20 | -0.05 |
| R&D Expense | 104.01K | 287.32K | 654.69K | 612.71K | 634.70K | 1.17M | 793.00K | 903.00K | 2.36M | 2.49M | 4.46M | 6.52M | 4.31M | 4.19M | 5.16M | 4.13M | 4.15M | 5.99M | 8.69M | 7.05M | 10.07M | 7.64M | 5.80M | 4.89M | 3.64M | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | - | 11.00K | 181.00K | 374.00K | 155.00K | 14.00K | 50.00K |
| Operating Income | -981.48K | -12.44M | -7.76M | -12.23M | -29.15M | -25.95M | -29.74M | -42.63M | -47.38M |
| Net Income | -831.49K | -12.44M | -7.68M | -12.10M | -30.34M | -27.30M | -30.01M | -42.08M | -45.93M |
| Diluted EPS | - | - | - | - | -1.88 | -1.52 | -1.67 | -2.11 | -1.86 |
| R&D Expense | 435.36K | 3.35M | 3.28M | 5.92M | 20.54M | 17.07M | 20.27M | 33.17M | 20.66M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 18.41M | 17.36M | 24.47M | 40.66M | 99.94M | 81.80M | 57.00M | 39.56M | 32.35M |
| Total Equity | -149.20K | 18.10M | 16.54M | 23.61M | 38.75M | 80.22M | 60.10M | 37.34M | 32.10M | 23.52M |
| Cash & Equivalents | 141.66K | 1.37M | 186.20K | 7.00M | 21.97M | 74.81M | 52.15M | 35.85M | 20.92M | 24.75M |
| Long Term Debt | - | - | - | - | - | 15.00M | 9.70M | - | 15.00M | - |
| Total Liabilities | - | 309.72K | 823.77K | 860.54K | 1.90M | 19.72M | 21.69M | 18.86M | 7.46M | 8.83M |
| Current Liabilities | - | - | 823.77K | 700.38K | 1.78M | 4.36M | 10.92M | 18.46M | 7.22M | 8.42M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -761.83K | -2.06M | -5.38M | -8.94M | -28.50M | -22.69M | -11.98M | -33.36M | -22.58M |
| Investing Cash Flow | -100.00K | - | - | - | -15.00M | - | - | - | -1.04M |
| Financing Cash Flow | 2.06M | 900.00K | 12.21M | 23.89M | 96.36M | 729.00K | -4.22M | 18.21M | 27.61M |
| Capital Expenditure | - | - | - | - | - | - | - | - | -1.04M |
| Free Cash Flow | - | - | - | - | - | - | - | - | -23.62M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | -111,163.6% | -16,106.6% | -6,938.8% | -19,187.7% | -304,535.7% | -94,766.0% |
| Net Margin % | - | - | - | -109,990.9% | -16,762.4% | -7,299.2% | -19,360.0% | -300,585.7% | -91,866.0% |
| ROE % | -4.6% | -75.2% | -32.5% | -31.2% | -37.8% | -45.4% | -80.4% | -131.1% | -195.3% |
| ROCE % | - | -75.2% | -32.6% | -31.5% | -30.5% | -36.6% | -77.2% | -131.8% | -198.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Vanguard Capital Management LLC | 2.55% | 706.42K | $1.65M |
| 2 | AQR Capital Management, LLC | 2.39% | 662.22K | $1.54M |
| 3 | Blackrock Inc. | 1.12% | 311.61K | $726.06K |
| 4 | Raymond James Financial, Inc. | 0.77% | 213.00K | $496.28K |
| 5 | Geode Capital Management, LLC | 0.69% | 190.22K | $443.20K |
| 6 | Goldman Sachs Group Inc | 0.67% | 185.25K | $431.62K |
| 7 | Millennium Management Llc | 0.57% | 159.56K | $371.77K |
| 8 | Susquehanna International Group, LLP | 0.57% | 158.45K | $369.19K |
| 9 | Jane Street Group, LLC | 0.48% | 134.23K | $312.76K |
| 10 | UBS Group AG | 0.40% | 110.41K | $257.26K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for INMB
INmune Bio schedules Aug. 6 webcast on second-quarter results - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxPV3ZzTmREN044MVNtUjlGNklWQUJWLXhZelZObkJMUHVfV2g4YTVjeXd6TnN4RFJyX2otX2pISzJKaEdKdXc1Wk5KMnB0Y0J5QW95ZTROdU9KZE5QeUx6dW9tTG1iRDJpeGVSenM5Q3RXemhEczBRdE1VY0JOdVBiWG11blNaUzlyemplVl…
INMUNE BIO ($INMB) Releases Q1 2026 Earnings | INMB Stock News - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxOb3IwNGlaNHgyRlU1aXZPRDRZNlJ6V2VqTkl4TU1pbmo0aTJtTmhFUUpnWGN6dmVIT1N1Y2M3ZUMzZWF2SjhROVdhLXRUaUNVVk1MUVNTb0lPMmRoc0pSUGpaOXdObTNxVUhramd1ZnVDX0VrbWQ3cFlYaG5jNjlZZUtHa2tYVnVnUnkw?o…
INMB Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTFAzdlhWYWQ4Nld6TzZCX0ZtbzdqajIzeVJ5Y2ZWS2JqNWpncGlhbzAycmRremNhdXZ5TWZZWHFscWFtMzgzR1UxTDlfMEJWRWFxUDJvOHh3Mm80Sk9nMjZiNkd0YUdOSnhJLVhreURrR0VDR2cyR1BsZGVB?oc=5" target="_blank">INM…
INMB - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE1ieDFjd3dNTmhoX1ZnZFJ5QjJfcFlQM09mcHNTd2JBSGVRM1dyRHZsdGlZX2dLbkpjQnU0TFBPSXNsdkVqS1E?oc=5" target="_blank">INMB</a> <font color="#6f6f6f">Finviz</font>…
INmune Bio (NASDAQ:INMB) Will Have To Spend Its Cash Wisely - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxQeGVtSVREV0RtU2NPd0RLdkJ6XzdoSERMdXJveVVOTWhrNU5pd0RKWEMzVjBvSlk3WFZudl9ERERlVnRIaVIxLWFUMVFXdEdrdHlTWnlxdU9YYVFPb28yMVpLTkV1T2RUc1JlVXRXN1ZVNk9PUVFIMkIyUS1NT1Iyc0RvNzN6UFcyQjFYT2…
Rare Stock Picks In August 2026 - From 21 Discerning Analysts - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxOWVNPZ0lxak1TVVVqNjZ6Z1BFRWx2WlhGRzFIVV9hdEdrVEZwNkFobElUVlBHTnZfcXlGVzZiZGNYSWMwNHhiTngxeHpVaGNlRzFqeTNCX3lTU0xha19JNlAzWXlaVTYwQ0dWTlRMX3YzVFBpaHc5S2p4UHE0ZnE5X0pLT0pUc3dTdnA5Mm…
INMB — Frequently Asked Questions
What is the current share price of INmune Bio Inc. (INMB)?
As of 2026-09-07 16:24 PDT, INmune Bio Inc. (INMB) trades at $2.44 on NasdaqCM. Its 52-week range is $1.12 to $2.56.
What is the market capitalisation of INMB?
INmune Bio Inc. (INMB) has a market capitalisation of $64.87M on NasdaqCM.
What is the P/E ratio of INMB?
INMB trades at a trailing price-to-earnings (P/E) ratio of -1.50. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 2.83.
Is INMB a good stock to buy?
This page provides a data-driven analysis of INmune Bio Inc. (INMB), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.